Search
AGS-005
go.drugbank.com/drugs/DB05741ExperimentalAGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's
Mianserin
go.drugbank.com/drugs/DB06148ApprovedWithdrawnA tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMyrcludex B
go.drugbank.com/drugs/DB14853InvestigationalWith Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D). … Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination
Bambermycins
go.drugbank.com/drugs/DB11377ExperimentalVet approvedThey are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.
RPI-MN
go.drugbank.com/drugs/DB17957Experimental[A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]
IMM101
go.drugbank.com/drugs/DB15851ExperimentalStudies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039].
DPDPE
go.drugbank.com/drugs/DB08861ExperimentalA heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeUpanovimab
go.drugbank.com/drugs/DB16505InvestigationalUpanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19
Human umbilical cord blood mononuclear cell-conditioned medium
go.drugbank.com/drugs/DB15724ExperimentalThus, the media in which they are cultured is believed to also have therapeutic potential. … When HUCBCs secrete growth factors and anti-inflammatory cytokines, they are thought to reduce inflammation and associated damage.